Here's a new twist in the weight-loss drug saga: you can now get more of a good thing. The U.S. Food and Drug Administration said yes on Thursday to a higher-dose version of Novo Nordisk A/S's (NVO) blockbuster drug, Wegovy. This isn't for new patients; it's for people already on the medication who need an extra push for more weight reduction.
The approval came through a special fast-track program, and the new dose—Wegovy HD (semaglutide) injection 7.2 mg—is specifically for patients who have handled the current 2.4 mg dose just fine but want to lose more weight. Of course, it's still meant to be used with the classic combo of eating fewer calories and moving more.
So, what's the evidence? The FDA's decision leans on data from the STEP UP clinical program, including a 72-week study. That trial involved 1,407 adults with obesity (a BMI of 30 or higher) who didn't have diabetes. The results were clear: people getting the 7.2 mg dose lost significantly more weight than those on a placebo or even the standard 2.4 mg Wegovy dose.
For Novo Nordisk, this is about more than just offering a stronger dose. Jamey Millar, the company's executive vice president of U.S. operations, said the approval "reinforces Wegovy's clinical profile." He pointed out that Wegovy remains the only GLP-1 therapy for obesity that's been proven to cut the risk of major heart problems—like stroke, heart attack, and cardiovascular death—in patients who already have heart disease. Before this, the top dose was 2.4 mg, which already had those weight-loss and heart-risk reduction claims on its label. Now, the portfolio just got a more potent option.
When can patients get it? Novo Nordisk says Wegovy HD will start hitting shelves (and digital carts) in April. It'll be available at over 70,000 pharmacies across the U.S., including the big chains and telehealth platforms. The company also plans to offer it through its own NovoCare Pharmacy and savings programs to help lower out-of-pocket costs for eligible users.
This approval is part of a bigger push to expand access to these popular medications. Just a day before the FDA news, Hims & Hers Health, Inc. (HIMS) announced a collaboration with Novo Nordisk. The deal will let Hims & Hers offer access to the only FDA-approved GLP-1 weight-loss pill, along with injectable Wegovy in all its dosages. They also plan to offer Ozempic injections at cash-pay prices starting at $149 a month and have set up an "exclusive pre-launch waitlist" to give customers a heads-up on availability and pricing.
The U.S. isn't the only market moving on this. Back in January, the U.K.'s medicines regulator approved the 7.2 mg dose. Over in the European Union, the key medicines committee has given it a positive thumbs-up, and Novo Nordisk expects a final regulatory decision there in the first quarter of 2026.
Despite the good news, Novo Nordisk's shares were down about 2% on Thursday. Sometimes the market reacts in ways that don't seem to match the headlines.
